BACKGROUND Concurrent chemoradiotherapy is the standard treatment for anal cancer. Following national UK implementation of intensity-modulated radiotherapy (IMRT), this prospective, national cohort evaluates the one-year oncological outcomes and patient-reported toxicity outcomes (PRO) after treatment. MATERIALS AND METHODS A national cohort of UK cancer centers implementing IMRT was carried out between February to July 2015. Cancer centers provided data on oncological outcomes, including survival, and disease and colostomy status at one-year. EORTC-QLQ core (C30) and colorectal (CR29) questionnaires were completed at baseline and one-year followup. The PRO scores at baseline and one year were compared. RESULTS 40 UK Cancer Centers returned data with a total of 187 patients included in the analysis. 92% received mitomycin with 5-fluorouracil or capecitabine. One-year overall survival was 94%; 84% were disease-free and 86% colostomy-free at one-year followup. At one year, PRO results found significant improvements in buttock pain, blood and mucus in stools, pain, constipation, appetite loss, and health anxiety compared to baseline. No significant deteriorations were reported in diarrhea, bowel frequency, and flatulence. Urinary symptom scores were low at one year. Moderate impotence symptoms at baseline remained at one year, and a moderate deterioration in dyspareunia reported. CONCLUSIONS With national anal cancer IMRT implementation, at this early pre-defined time point, one-year oncological outcomes were reassuring and resulted in good disease-related symptom control. one-year symptomatic complications following CRT for anal cancer using IMRT techniques appear to be relatively mild. These PRO results provide a basis to benchmark future studies.

中文翻译：

---

接受调强放疗治疗的英国国家肛门癌队列：一年的肿瘤学和患者报告的结果。

背景技术同步放化疗是肛门癌的标准治疗方法。在英国实施调强放疗 (IMRT) 之后，这个前瞻性的国家队列评估了治疗后一年的肿瘤学结果和患者报告的毒性结果 (PRO)。材料和方法 在 2015 年 2 月至 7 月期间，对实施 IMRT 的英国癌症中心进行了全国队列研究。癌症中心提供了关于肿瘤学结果的数据，包括生存率、疾病和结肠造口状态。EORTC-QLQ 核心 (C30) 和结肠直肠 (CR29) 问卷在基线和一年的随访中完成。比较基线和一年的 PRO 分数。结果 40 个英国癌症中心返回数据，共有 187 名患者被纳入分析。92% 接受了丝裂霉素和 5-氟尿嘧啶或卡培他滨。一年总生存率为 94%；在一年的随访中，84% 无病，86% 无结肠造口术。一年后，PRO 结果发现与基线相比，臀部疼痛、便血和粘液、疼痛、便秘、食欲不振和健康焦虑有显着改善。腹泻、排便频率和肠胃胀气没有明显恶化的报告。一年时泌尿系统症状评分较低。基线时的中度阳痿症状持续一年，据报道性交困难有中度恶化。结论 随着国家肛门癌 IMRT 的实施，在这个早期的预定义时间点，一年的肿瘤学结果令人放心，并导致了良好的疾病相关症状控制。使用 IMRT 技术对肛门癌进行 CRT 后一年的症状并发症似乎相对轻微。这些 PRO 结果为未来研究的基准提供了基础。